Romani L et al., 2015-12-10: Community-randomized trial in three Fijian island communities in which mass administration of ivermectin cut scabies prevalence by 94% at 12 months, far more than permethrin mass treatment (62%) or standard care (49%).
The prevalence declined from 36.6% to 18.8% in the standard-care group (relative reduction in prevalence, 49%; 95% confidence interval [CI], 37 to 60)
Romani L et al., 2015-12-10: Community-randomized trial in three Fijian island communities in which mass administration of ivermectin cut scabies prevalence by 94% at 12 months, far more than permethrin mass treatment (62%) or standard care (49%). Randomized trial allocating three island communities to standard care (permethrin to affected persons and contacts, n=803), mass permethrin (n=532) or mass ivermectin (n=716); N=2051 enrolled, Fiji, 12-month follow-up. Ivermectin arm: prevalence 32.1% to 1.9% (relative reduction 94%, 95% CI 83-100); impetigo 24.6% to 8.0%. Adverse events mild but more frequent with ivermectin than permethrin (15.6% vs 6.8%). Funded by the Australian National Health and Medical Research Council; ACTRN12613000474752. The exact ivermectin dose and number of rounds are not in the abstract and the full text is paywalled, so they are not stated here rather than guessed. Quote is a continuous passage from the abstract; the following clause in the same sentence gives the permethrin and ivermectin arms. Study type: randomized trial.
